Can Tolvaptan Cause Liver Injury?
Yes, tolvaptan causes hepatotoxicity in approximately 4-6% of patients with autosomal dominant polycystic kidney disease (ADPKD), manifesting as hepatocellular injury with elevated liver enzymes that typically occur within the first 18 months of treatment. 1, 2
Incidence and Timing of Hepatotoxicity
The incidence of alanine aminotransferase (ALT) or aspartate aminotransferase (AST) elevations ≥3× the upper limit of normal (ULN) ranges from 4.4% to 5.6% in clinical trials and 3.6% in post-marketing surveillance, compared to approximately 1% with placebo. 1, 2, 3
Hepatocellular injury typically manifests between 3 and 18 months after therapy initiation, with the majority of cases occurring within the first 18 months of treatment. 1, 4
After the initial 18-month period, the frequency of liver enzyme elevations decreases substantially. 1, 2
Reversibility and Prognosis
Elevations in liver enzymes are generally reversible, returning to baseline within 1–4 months after drug discontinuation. 1, 4
Importantly, no cases meeting Hy's Law criteria (ALT >3× ULN with concurrent total bilirubin >2× ULN) have been reported in the REPRISE trial or long-term extension studies, suggesting a lower risk of severe, potentially fatal liver injury. 2, 3
All documented DILI events in clinical trials have resolved following tolvaptan cessation. 2, 3
Mandatory Monitoring Protocol
The KDIGO 2025 guidelines provide explicit monitoring requirements that must be followed:
Monthly liver function tests (AST, ALT, bilirubin) for the first 18 months of treatment. 1, 4, 5
After 18 months, conduct liver tests every 3 months until medication discontinuation. 1, 4, 5
If ALT or AST rises to >2× ULN or >2× baseline, obtain repeat testing within 48–72 hours. 1, 4
When to Hold or Discontinue Tolvaptan
Immediate hold is required when:
- AST or ALT ≥3× ULN. 1, 4
- AST or ALT >2× baseline (even if still <2× ULN). 1, 4
- Multiple liver-injury symptoms appear: fatigue, nausea, vomiting, anorexia, right-upper-quadrant pain, fever, rash, jaundice, pruritus, or ascites. 1, 4
Permanent discontinuation is mandated unless an alternative explanation for the liver injury is identified and the hepatic injury has completely resolved. 1, 4
Contraindications Related to Liver Safety
Tolvaptan must not be initiated in patients whose baseline liver enzymes are >3× ULN, as this indicates pre-existing liver disease. 4
Rechallenge is prohibited in patients who have experienced hepatic injury or transaminase elevations ≥3× ULN unless a different cause is confirmed, per FDA labeling. 1, 4, 6
Tolvaptan should not be used for ADPKD outside of the FDA-approved Risk Evaluation and Mitigation Strategy (REMS) program due to hepatotoxicity risk. 6
Mechanisms of Hepatotoxicity
In vitro studies have identified alterations in bile acid disposition and inhibition of mitochondrial respiration as potential mechanisms underlying tolvaptan hepatotoxicity. 7
Animal studies in polycystic kidney disease models demonstrate decreased biliary clearance and increased hepatocellular concentrations of tolvaptan and its metabolites (DM-4103 and DM-4107), which may contribute to liver injury specifically in ADPKD patients. 8
The toxicity appears to be multifactorial, involving both bile acid transporter inhibition and mitochondrial dysfunction. 7
Special Considerations and Drug Interactions
Strong CYP3A inhibitors (antifungals, certain antibiotics, protease inhibitors) and grapefruit juice should be avoided, as they increase tolvaptan exposure and potentially hepatotoxicity risk. 4, 5, 6
A case report documented hepatotoxicity from the combination of tolvaptan and amoxicillin/clavulanic acid, highlighting the need for careful monitoring when antibiotics are co-administered. 9
Why ADPKD Patients Are Specifically at Risk
Notably, no liver injury has been observed with tolvaptan treatment in healthy subjects or in non-ADPKD indications (such as hyponatremia), despite the same drug exposure. 7
This suggests that the ADPKD disease state itself may predispose patients to tolvaptan-induced liver injury, possibly through altered hepatobiliary drug disposition. 7, 8
Pediatric Considerations
Tolvaptan is not routinely recommended for children and young people with ADPKD, and the impact on liver enzymes in children is not yet known. 1
Off-label use can be considered at clinician discretion in high-risk pediatric patients, but with heightened awareness of hepatotoxicity risk. 1, 5
Critical Clinical Pitfalls to Avoid
Failure to perform monthly monitoring during the first 18 months is the most common error, as this is when most hepatotoxicity occurs. 1, 4
Delaying discontinuation when transaminases reach ≥3× ULN can lead to progression of liver injury. 1, 4
Attempting rechallenge after significant liver injury (≥3× ULN) is contraindicated and dangerous. 1, 4
Ignoring symptoms of liver injury (fatigue, nausea, right upper quadrant pain, jaundice) between scheduled monitoring visits can result in delayed recognition of hepatotoxicity. 1, 4